Vogenx, Inc. (VOGX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Vogenx, Inc. (VOGX) closed at USD 19.92 on 2026-10-29, a change of +53.2 % over the past year, with a market capitalization of USD 300.82M.

Vogenx, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Vogenx, Inc. key figures

Previous close

USD 19.92 (2026-10-29)

1-year change

+53.2 %

Market cap

USD 300.82M

Enterprise value

USD 301.49M

P/E ratio (trailing)

-92.05

P/E ratio (forward)

n/a

EPS (trailing)

-0.22

EPS (forward)

n/a

PEG ratio

n/a

Price to book

-59.91

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.29

Employees

4

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Vogenx, Inc.

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Vogenx, Inc. and compare it with other stocks.